Borderline Insanity? Drug Importation May Get New Life in 2007
This article was originally published in RPM Report
Executive Summary
After receding into political obscurity for several years, drug importation has come back into focus on Capitol Hill. The chances for legislation getting through Congress and past a presidential veto are a long shot, but Wall Street is worried.
You may also be interested in...
Product Liability Forecast: More Suits, Smaller Scale
More than 20 drugs are the subject of multidistrict product liability litigation, but none of the pending cases approach the scope of past lawsuits against Merck’s Vioxx and Lilly’s Zyprexa. That may be one silver lining for Big Pharma as the blockbuster era draws to a close.
Product Liability Forecast: More Suits, Smaller Scale
More than 20 drugs are the subject of multidistrict product liability litigation, but none of the pending cases approach the scope of past lawsuits against Merck’s Vioxx and Lilly’s Zyprexa. That may be one silver lining for Big Pharma as the blockbuster era draws to a close.
Reimportation Revived? Or an Issue about to Expire?
Support for reimportation of lower-priced drugs from outside the US has been a rallying point for Democratic critics of the drug industry for almost a decade. But there are signs that some influential Democrats now view it as a distraction from the real target-cutting drug costs here.